Emergent Biosolutions Inc. (NYSE:EBS) Shares Purchased by Cetera Investment Advisers

Key Points

• Cetera Investment Advisers increased its holdings in Emergent Biosolutions Inc. by 28.5%, owning a total of 356,281 shares valued at approximately $1.73 million as of the latest SEC filing.
• Many institutional investors are active in Emergent Biosolutions, with entities like Millennium Management LLC and Invesco Ltd. significantly raising their stakes, indicating strong institutional interest in the biopharmaceutical firm.
• Emergent Biosolutions reported $0.16 earnings per share for the last quarter, surpassing expectations, despite revenue falling short of estimates at $140.90 million.

Cetera Investment Advisers raised its holdings in shares of Emergent Biosolutions Inc. (NYSE:EBS - Free Report) by 28.5% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 356,281 shares of the biopharmaceutical company's stock after acquiring an additional 79,034 shares during the quarter. Cetera Investment Advisers owned approximately 0.66% of Emergent Biosolutions worth $1,732,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in the company. LPL Financial LLC increased its position in Emergent Biosolutions by 34.5% during the 4th quarter. LPL Financial LLC now owns 15,120 shares of the biopharmaceutical company's stock worth $145,000 after purchasing an additional 3,875 shares during the period. Geode Capital Management LLC lifted its position in shares of Emergent Biosolutions by 1.5% in the fourth quarter. Geode Capital Management LLC now owns 590,862 shares of the biopharmaceutical company's stock valued at $5,651,000 after acquiring an additional 8,904 shares in the last quarter. Envestnet Asset Management Inc. acquired a new stake in shares of Emergent Biosolutions during the fourth quarter worth $331,000. Federated Hermes Inc. boosted its holdings in shares of Emergent Biosolutions by 2.2% during the fourth quarter. Federated Hermes Inc. now owns 277,810 shares of the biopharmaceutical company's stock worth $2,656,000 after purchasing an additional 6,058 shares during the last quarter. Finally, Invesco Ltd. boosted its holdings in shares of Emergent Biosolutions by 70.9% during the fourth quarter. Invesco Ltd. now owns 1,539,907 shares of the biopharmaceutical company's stock worth $14,722,000 after purchasing an additional 638,995 shares during the last quarter. 78.40% of the stock is owned by hedge funds and other institutional investors.

Emergent Biosolutions Stock Up 9.3%

Shares of NYSE:EBS traded up $0.76 during trading on Tuesday, hitting $8.92. The company's stock had a trading volume of 1,764,885 shares, compared to its average volume of 1,256,944. The company has a debt-to-equity ratio of 1.25, a quick ratio of 3.00 and a current ratio of 5.66. Emergent Biosolutions Inc. has a fifty-two week low of $4.02 and a fifty-two week high of $13.28. The stock's 50-day moving average price is $6.76 and its two-hundred day moving average price is $6.59. The company has a market capitalization of $475.88 million, a PE ratio of 3.64 and a beta of 1.97.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $0.16 earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.42. The firm had revenue of $140.90 million during the quarter, compared to analyst estimates of $148.55 million. Emergent Biosolutions had a return on equity of 24.63% and a net margin of 16.38%. As a group, sell-side analysts expect that Emergent Biosolutions Inc. will post -0.63 EPS for the current year.

Analyst Ratings Changes

Separately, Wall Street Zen lowered Emergent Biosolutions from a "buy" rating to a "hold" rating in a research report on Saturday.

Insider Activity at Emergent Biosolutions

In other news, Director Keith Katkin sold 7,844 shares of the business's stock in a transaction that occurred on Friday, May 23rd. The stock was sold at an average price of $6.30, for a total transaction of $49,417.20. Following the completion of the transaction, the director directly owned 86,431 shares in the company, valued at approximately $544,515.30. The trade was a 8.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 3.20% of the company's stock.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.